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ABSTRACT 
The aim of the present study was to develop and characterise polymeric composite pellets by 
means of continuous melt extrusion techniques.  Powder blends of a steroid hormone (SH) as a 
model drug and either ethyl cellulose (EC N10 and EC P7 grades) or hydroxylpropyl 
methylcellulose (HPMC AS grade) as polymeric carrier were extruded using a Pharma 11 mm 
twin screw extruder in a continuous mode of operation to manufacture extruded composite 
pellets of 1 mm length.  Molecular modelling study using commercial Guassian 09 software 
outlined a possible drug-polymer interaction in the molecular level to develop solid dispersions 
of the drug in the pellets. Solid-state analysis conducted via a differential scanning calorimetry 
(DSC), hot stage microscopy (HSM) and X-ray powder diffraction (XRPD) analyses revealed 
the amorphous state of the drug in the polymer matrices. Surface analysis using SEM/energy 
dispersive X-ray (EDX) of the produced pellets arguably showed a homogenous distribution of 
the C and O atoms in the pellet matrices. Moreover, advanced chemical surface analysis 
conducted via atomic force microscopy (AFM) showed a homogenous phase system having the 
drug molecule dispersed onto the amorphous matrices while Raman mapping confirmed the 
homogenous single-phase drug distribution in the manufactured composite pellets. Such 
composite pellets are expected to deliver multidisciplinary applications in drug delivery and 
medical sciences by e.g. modifying drug solubility/dissolutions or stabilizing the unstable drug 
(e.g. hormone, protein) in the composite network. 
 
Keywords: Amorphous, steroid hormone, ethyl cellulose, composite, continuous manufacturing, 
surface analysis. 
  
  
1. Introduction 
The term ‘continuous manufacturing’ in pharmaceutical sphere is referred to a process 
where pharmaceutical materials are produced in a continuous mode of operation with the scope 
of real time process monitoring [1]. In reality, the batch manufacturing that is the currently 
adopted manufacturing process, tests the products off-line after processing is complete lacking 
the opportunities of real time monitoring [1]. In contrary, the continuous manufacturing renders 
numerous benefits including those automated processing with less intermediate steps, flexible 
and cost effective operation. Besides, unlike the batch processing, continuous manufacturing also 
provides windows for on-line/in-line monitoring and product quality assurance for real time 
analysis [1-3]. 
Hot-melt extrusion (HME) has emerged and been employed as a novel manufacturing 
technique for the manufacture and development of various drug delivery systems over the last 
few decades [1]. Whilst, HME by itself is capable of integrating manufacturing process in a 
continuous mode of operation, a suitable exploitation of this emerging technique in 
pharmaceutical sphere has not yet been completely established [1]. The compatibility with a 
wider range of down streaming processing tools has HME one of most versatile manufacturing 
technology to produce pellets, granules, tablets, capsules and films with different therapeutic 
effects. These therapeutics effects can range from modified/controlled release through the 
mucosal or buccal delivery to medical implants and biodegradable composites [2, 5]. Though in 
the early eighty’s when HME was first introduced in pharmaceutical research, the initial research 
had primarily focused on the processing variables and instrumentations and their optimized use 
in the pharmaceutical drug delivery, more recent investigations have focused on the use of HME 
as a novel manufacturing technology to the development of medical implants, composite 
materials and nano-scale drug delivery systems [6,7].
 
Early studies via HME reported the 
manufacture of mini-tablets and the effect of the processing onto the sustained release of those 
drug loaded mini-tablets. The study reported that the manufactured mini-tablets contained ethyl 
cellulose and HPMC as polymeric carrier while poorly water soluble ibuprofen as a model drug 
[8, 9]. Similarly, vegetable calcium stearate (CaSt) was exploited as a suitable carrier to develop 
paracetamol loaded pellets to display a slow release of the drug [10].  Later studies showed the 
successful implementation of HME technique to manufacture and fabricate microbicide 
intravaginal ring (IVR) from polyether urethane (PU) elastomers. UC781 which is a nucleoside 
  
reverse transcriptase inhibitor of HIV-1 was utilized as a model drug to treat AIDS [11].
 
These 
published reports so far have not only yielded many positive results but also many unanswered 
questions. For example: the detailed interpretation/description of the interactions between the 
drug and polymers used to develop solid dispersions/ dosage forms; the identity and validity of 
the manufactured products via a continuous platform and issues relating to the commercial scale-
ups [1].  
The optimisation and a combined formulation development strategy may prove efficient 
to develop novel composite materials [12-14] that controls the release of the drug and/or stabilise 
the physical state of the drug molecules in the composite matrices [15].  It has been reported that 
an optimized dosage form approach can overcome this problem to a certain extent; however, it 
requires a primeval manufacturing platform [16, 17]. It is therefore the purpose of this study to 
implement a continuous manufacturing HME processing to develop and characterize the 
composite pellets of a steroid hormone (SH) that can provide e.g. a sustained release of the drug 
for a prolonged period of time or overcome any associated physico-chemical (e.g. stability and 
compatibility) and technological (e.g. ease of operation, ease of scale up) issues. A formulation 
development strategy via continuous manufacturing of the novel SH composite pellets are hereby 
reported and the characterization of the drug polymer interactions and drug distribution in the 
composite pellets are studied. 
 
2. Materials and method 
2.1 Materials 
Steroid hormone (SH) and PEG 2000 (PEG) were purchased from Sigma-Aldrich 
(Gillingham, Dorset, UK). Ethyl Cellulose N10 (EC N10), ethyl Cellulose EP7 (EC P7), HPMC 
AS-LF (HPMC) and compritol ATO-888 (C-888 were kindly donated by Hercules (Darmstadt, 
Germany), Colorcon Ltd. (Dartford, UK) and ShinEtsu (Japan) and Gattefosse (Toulouse, 
France), respectively. All solvents were bought from Fisher Chemicals (Loughborough, UK) and 
were of analytical grades. 
2.2 Calculation of solubility parameters 
Solubility parameters [18] were determined for the assessment of the possible miscibility 
of the drug with different polymers and were determined by utilizing the Hoftyzer and Van 
Krevelen method [19] as shown in the equation below: 
  
222
hpd    (1) 
Here, 
i
di
d
V
F
  ,  
i
pi
p
V
F

2
   ,  )/( ihih VE  
i = structural groups within the molecule, δ =   the total solubility parameter. Fdi = molar 
attraction constant due to molar dispersion forces, F
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pi = molar attraction constant due to molar 
polarization forces, Ehi = hydrogen bonding energy, and Vi = molar volume. 
2.3 Molecular Modelling 
The dimeric structures of ethyl cellulose, HPMC and SH were computed by 
computational chemistry program Gaussview 09 [20].
 
The drug molecule was placed within the 
closeness of the dimeric structure of the polymer to outline the hydrogen bonding followed by 
the energy optimisation at the B3LYP 6-31G* level. The binding energy was calculated via a 
single point energies at the M06-2x/6-31G** level [16, 21]. The effect of basis set superposition 
error (BSSE) was corrected by employing counterpoise procedure.
 
2.4 Preparation of formulation blends and continuous HME processing 
All SH formulations (as shown in Table 1) with EC N10, EC P7, HPMC/PEG and 
HPMC/C-888 were mixed in a Turbula TF2 mixer (Basel, Switzerland) in 100 g batches for 10 
min each, prior to conducting the extrusion. Extrusion of all formulations were performed using 
a Pharma 11 twin-screw extruder (ThermoFisher, Germany) at 50
o
C/130°C/140°C-
140°C/140°C/140°C (from feeding zone → Die) temperature profiles, 100 rpm screw speed. The 
extrudates (strands) produced were cut into pellets of 1 mm length using pelletizer 
(ThermoFisher, Germany).  
2.5 Scanning electron microscopy (SEM)/ EDX analysis 
SEM images of the flat cross-section of the pellets were captured using a cold-cathode 
field-emission gun scanning electron microscope (Hitachi SU8030 FEG-SEM, Japan) and 
Thermo-Noran (USA) EDX system with 30 mm
2
 Ultra-Dry window and Noran 7 software. The 
  
samples were glued with a double-sided carbon adhesive tabs and coated with carbon (Edwards 
306 high vacuum carbon evaporation) prior to the SEM/EDX analysis. The accelerating voltage 
was set at 8 kV. Principal components were extracted from the X-ray maps using Noran 7 
COMPASS software. The particle distribution on the surface area was characterized on the basis 
of chemical composition and morphology by using XPhase.  
2.6 Atomic force microscopy (AFM) 
An easyscan 2 (nanosurf, Switzerland) machine was used to take AFM photographs of 
the flat cross-sections of manufactured composite pellets on tapping mode by using tap 190Al-G 
cantilevers (BudgetSensors, Sofia, Bulgaria). The intermittent force between the oscillated tip 
and the substrate was kept to minimum by balancing the drive amplitude and the relative set 
point. SPIP software (Image Metrology, Hørsholm, Denmark) was utilised to analyse the images 
and for the data interpretations. 
2.7 Thermal analysis 
The solid state of the bulk drug, bulk polymers, mixtures of drug/polymers in different 
ratios and the pellets were studied by using a differential scanning calorimeter (DSC) 823e 
manufactured by Mettler-Toledo (Greifensee, Switzerland). Approximately, 3-5 mg of samples 
were weighed and taken in a sealed aluminium pans and heated at 10°C/min heating rates at the 
range of 25°C-250°C under an inert environment (nitrogen). The lids were pierced to allow the 
release of the excessive pressure generated upon heating.  
The thermal analysis of the drug in the formulations was studied using a hot stage 
microscopy (Olympus BX60 microscope, Olympus Corp., USA) with Insight QE camera 
(Diagnostic Instruments, USA) was used to monitor the sample transitions. A FP82HT hot stage 
controlled by a FP 90 central processor (Mettler Toledo, Columbus, OH) was used to maintain 
temperatures between 20 and 250
o
C while a spot advance software (Diagnostic Instruments, Inc.) 
was utilised to capture the images.  
 
2.8 Powder X-ray diffraction (XRPD) 
The crystallinity of the SH in different composites was evaluated by using a Bruker D8 
Advance (Germany) in theta-theta reflection mode with copper anode. For the purpose of the 
study pellets were ground to fine powders using a mortar and pestle prior to the analysis. A 
  
parallel beam Goebel mirror with 0.2 mm exit slit and LynxEye sensitive detector opening at 3 
degrees with 176 active channels was used. Each sample was scanned from 2 to 40 2θ with a 
step size of 0.02 2θ. Data collection and interpretations were performed using DiffracPlus and 
the the EVA V.16 program, respectively. 
2.9 Raman mapping 
Raman spectra of bulk substances as well as the flat cross-section of the pellets were 
obtained at ambient using a Jobin/Yvon LabRam 320 instrument (1800 grooves/mm holographic 
grating, a holographic notch filter, a Peltier-cooled CCD (MPP1 chip) for detection) and an 
Olympus BX40 microscope equipped with an Olympus microscope (Horiba, Japan). An Ar+ ion 
laser (λ = 532.8 nm) was used. Raman spectra of the pellets were collected at ambient on a 
microscope slide using a microscope objective of 50 × magnification to focus the laser beam. A 
backscattering (180° between excitation and collection) geometry was used in all experiments. 
Each spectral scan was collected for 5 s using 4 accumulations. The Raman instrument was 
calibrated using the v1 line of silicon at 520.7 cm
−1
. Using the frequencies of the principal lines 
of a neon lamp checked centering of the silicon line. The experimental conditions for Raman 
mapping of the pellets were: 100 nm slit width, a 50× Microsoft objective and 0.4 s acquisition 
time. Each spectrum was the mean of the two. The sample profiling was performed at step 
increments of 3 μm in the X–Y direction covering the biggest possible surface of the part.  
3. Results and discussion 
3.1 Solubility parameters and molecular modelling 
The drug/polymer miscibility was estimated by correlating the energy of mixing from 
inter and intra-molecular interactions of the materials used (drug and polymers) [19].  For this 
purpose, the Hansen parameters (δ) calculated based on the structural orientation of the 
component informs that the drug-polymers with similar δ values used in a system are likely to 
interact with each other as matter of being miscible. It has widely been accepted that two 
compounds are generally treated miscible when Δ is less than 7 MPa1/2 (17, 20) [19]. The 
higher values of Δ (>7 MPa1/2) between a drug/polymer pair generally indicates an 
immiscibility. In general term, the miscibility is achieved by balancing the energy of mixing 
released by inter-molecular interactions with that of intra-molecular interactions within the 
components [22, 23]. In this study, the calculated solubility parameters of SH, EC N10, EC P7 
  
and HPMC are 22.60, 25.61, 25.27 and 25.30 MPa
1/2
, respectively.
 
The difference between the 
calculated solubility parameters of each drug/polymer pair indicates that SH is likely to be 
miscible with all polymers. The Δδ values reported for SH/EC N10, SH/EC P7 and SH/HPMC 
are 3.01, 2.67 and 2.70 MPa
1/2
, respectively. As a result, based on the theoretical calculations, the 
miscible systems should result in the formation of molecular solid dispersions. Similar claims 
have been made previously in various literature [22, 23]. In order to interrelate the theoretical 
calculations to that of experimental findings, the solid state thermal analysis (see DSC section for 
more details) should reveal a single glass transition (Tg) at an intermediate temperature between 
the Tgs of the amorphous polymer and the amorphous drug, if a molecular dispersion is formed. 
Moreover, due to the strong miscibility as determined herein by the solubility parameters, the 
drug molecules are expected to have been entrapped in the composite matrices to form solid 
dispersions at a molecular level. This has been validated by solid state analyses below. As a 
matter of fact, all manufactured composite pellets showed a homogenous drug dispersion 
throughout the manufactured pellets (see surface analysis sections).  
Quantum mechanical (QM)-based molecular modelling approach was utilised to compute 
the binding energy between the drug and the polymers by considering total energy of the system 
in all possible atomic co-ordinations. Any non-bonded interactions such as hydrogen bonds can 
be calculated precisely via the QM approach adopted in this study. The calculated binding 
energy represents the strengths of the hydrogen bonds between the drug and polymers (Fig. 1). 
The calculated binding energy indicated that the interactions and thus the possible miscibilit y 
between the drug molecule and the polymers are quite high ranging from 15-25 kcal/mol 
resemblance of the numbers of H-bonds. Similar to the solubility parameters calculations, it can 
be claimed via the QM approach that the higher the binding energy the more stable the 
drug/polymer interactions to develop the solid dispersions in the composites [16]. 
 
3.2 Manufacturing of composite pellets 
Extrusion processing optimised to obtain the extrudates as white composite pellets of 1 
mm length is depicted in Fig. 2. The temperature profiles, screw speed and the feed rate were 
found to be the critical processing parameters (CPP) for the development of the composite 
pellets. During the optimisation of the process to manufacture composite pellets, a range of 
temperatures profiles from 120
o
C-140
o
C were evaluated to assess the final outputs such as shear 
force, torque, feed rate and screw speed on the manufactured pellets. The optimised screw 
configuration provided intermediate levels of distributive mixing. This is typical of the type of 
  
screw configurations used in conventional polymer compounding (mixing) operations. 
Distributive mixing was achieved and optimised in the process during extrusion using a series of 
bi-lobal mixing/ kneading blocks or paddles. These blocks are of length equal to a quarter of the 
extruder screw diameter and were arranged at specified angles from the preceding element: 30, 
60 or 90° in the forward conveying direction. It is noted that a kneading block arrangement with 
a 30° mixing paddles provide the most forward conveying while 60° provide moderate to less 
and 90° provide complete mixing with zero forward conveying action.  
By keeping the final processing condition and the throughput of the 
drug/polymer/plasticizers powder blends, final batch of formulations extruded continuously at 
140
o
C with a feed rate of 1 kg/h and a high screw speed of 100 rpm produced polymeric strands 
with uniform shape and of about 1 mm diameter. The pellets obtained via an automated pelletizer 
consistently produced pellets of 1 mm length. 
 
3.3 SEM and EDX analysis 
SEM examined surface morphology for both the drug and extruded composite pellets. 
The extrudates containing both polymers exhibited no drug crystals on the extrudate surface with 
SH (Fig. 3a). A homogenous particle distribution was observed on the surface of manufactured 
pellets. SEM-EDX was performed to determine the distribution of SH in the continuously 
manufactured composite pellets. Both of the polymeric careers used mainly contain C and O 
atoms, similar to the drug. The distribution of SH was visualized by EDX elemental mapping of 
C and O only (Fig. 3b). The most occupied element was carbon (C) as it is the most abundant 
element comprising a majority of APIs and additives for oral drug delivery including SH and 
polymers used in this study. In this study, most of the phases showed a similar set of atomic 
textures due to the homogeneous distribution of the combined substances. Therefore, it was quite 
difficult to identify any specific phase in the absence of any marker atoms of the drug SH. 
However, this result provided evidence that the pellets were well formed in the intended drug–
polymer ratio without the occurrence of irregular content strain during the continuous production 
of pellets via HME processing. This irregular content strain could have been evident due to the 
presence of inhomogeneous drug/excipients distribution in the composite materials. It was also 
evaluated that the SH was homogenously dispersed into the particle matrix by EDX mapping 
  
study. Recently, there have been some reports about EDX mapping used for the observation of 
homogenous distribution of API on extruded formulations [17].  
3.4 Atomic force microscopy (AFM) 
AFM was applied, as a complementary technique [24] to investigate whether SH was 
dispersed/entrapped in matrices of the polymers/plasticizers (for F3 and F4) [25]. The AFM 
images of the composite pellets are illustrated in Fig. 4. The phase images in Fig. 4 showed that 
there is no phase separation between the components indicating that SH has been adsorbed by 
the carriers during the extrusion processing. Moreover, there was no sign of crystallisation on the 
surface, which also indicates the presence of the drug in amorphous state within the matrices. 
Fig. 4 also indicates that a homogenous mixing was performed during the continuous HME 
processing which could be due to the possible intermolecular interactions as outlined via the 
molecular modelling studies. The topographic AFM image demonstrates the roughness of the 
surface which is also is presented in the SEM results. Surface roughness were identified in the 
root mean square (RMS) value and has been estimated to be 132.26 (±62) nm. This roughness 
can be due to the manufacturing procedure. The observed results were consistent with all 
drug/polymer ratios with or without plasticizer for extruded formulations suggesting that even at 
high drug loading HME processing resulted in a homogenous single phase solid dispersions.   
3.5 Thermal analysis 
The thermal transitions of the bulk drug, polymers and the formulations were 
analysed by DSC. The overall findings from DSC results are summarized in Fig. 5a and 
b. The DSC scan of bulk SH in Fig. 5a showed an endothermic sharp transition due to its 
melting at 226.12 
oC (δH= 114.92 J/g). The bulk polymers showed thermal events (step 
change) at 133.01 
o
C, 117.61 
o
C and 128.21
o
C conforming to the Tgs of EC N10, EC P7 
and HPMC, respectively (Fig. 5a). Similar to the bulk drug, both crystalline PEG and C-
888 showed thermal events at 52.82 
o
C and 72.14 
o
C, respectively due to their meltings. 
All drug polymer physical blends showed endothermic transitions (Fig. 5b) due to the 
presence of the initial crystalline substances at slightly shifted positions. These crystalline 
melting peaks were not visible in all extruded composite pellets. The extruded 
formulations exhibited only one broad endothermic peak in the region of 47.83 to 49.19
o
C 
indicating the presence of the drug in the molecular dispersion state. Being trailed by the 
statment made in the solubility parameter section above, it is claimed that the 
  
intermediate position of the single endotherm in the extruded formulations between the 
Tgs of amorphous drug and the polymers indicates the formation of molecular solid 
dispersion [22, 23]. Also, according to Gordon Taylor equation in a miscibile 
drug/polymer system a broad single Tg would appear at an intermediate position of the Tgs 
of amorphous drug and the polymer [23].  
Thermal analysis conducted via HSM determined the thermal transitions due to the 
melting of crystalline SH within the polymer matrices as a function of heating. Various images 
of both the bulk drug and drug/polymer mixtures taken using HSM are depicted Fig. 5c. Bulk SH 
showed minimal thermal change upon heating up until 200-220
o
C (data not shown), 
complemented by the DSC findings (melting at 226
o
C). All composite extruded pellets showed 
complementary thermal events similar to the DSC analysis for an example, SH in ethyl cellulose 
matrices showed nominal API melting until reaching temperatures of 195-202
o
C followed by 
extensive/complete melting of the drug (Fig. 5c). Likewise, the drug/EC P7 system showed the 
extensive melting of the drug within the polymer matrix at slightly low temperature at 185
o
C. 
Similar complementing results were obtained for HPMC systems in the presence of PEG and C-
888. 
3.6 X-ray powder diffraction (XRD) analysis 
X–ray powder diffraction analysis was utilised to examine the API crystalline state. As 
depicted in Fig. 6 the diffractograms of pure SH presented distinct crystalline peaks at 5.75, 
14.50, 16.08, 17.42, 18.79, 19.42, 23.22, 29.21, 30.14 2θ.  
The physical mixture of all formulations presented identical peaks of the crystalline 
substances present in the system but at lower intensities suggesting that the drug retained its 
crystalline properties. No such crystalline distinct peaks were found any of the extruded 
formulations in ethyl cellulose polymeric systems. Similarly, no distinct intensity peaks 
corresponding to SH was observed in the diffractograms of the extruded formulations in the 
HPMC systems except for the low intense peak due to the presence of crystalline PEG/C-888 in 
the formulations.  The absence of SH intensity peaks in the extruded formulations simply 
indicates the presence of amorphous API. 
3.7 Raman mapping 
  
 Raman spectra and the mapping of the surface [26-29] of the composite pellets are depicted 
in Fig. 7 and 8. As it can be observed, SH has a characteristic peak at 1600-1700 cm
-1
, which has 
been used to investigate the distribution of the drug in the formulations by means of univariate 
analysis. Fig. 7 and 8 demonstrate the consistent and homogeneous distribution of SH in all the 
particle area in physical mixtures (red dot represents SH, green dot represents HPMC polymer 
and blue dots represents PEG/C-888) of F3 and F4, respectively. Also it shows that all other 
materials are homogeneously mixed in the formulation. In contrast, the extruded composite 
pellets demonstrates a homogeneous one phase system represented by a full green view which 
may indicate the presence of HPMC polymer and drug encapsulated within the polymer matrices 
as claimed by DSC and XRPD analysis above (F3). Similarly, the surface mapping of F4 (Fig. 8) 
shows a very different blue/dark background corresponidng to the polymer. The existence of the 
single phase homogenous system in all formulations indicates that the drug molecule has been 
encapsulated within the polymeric matrices. This could also happen due to the molecular 
interaction as a result of single-phase distribution [30]. 
 Histograms of all formulations (Fig. 7 and 8) showed that the major components of the 
formulations were identical in composition. A change in peak is observed because of the third 
component (PEG/C-888) of each formulations. 
 
4. Conclusions 
 In the current study HME was successfully utilised as a robust continuous manufacturing 
platform to develop SH loaded composite pellets. Molecular modelling simulation used as a 
predictive tool to estimate the possible drug-polymer miscibility/interactions to develop 
composites showed a strong binding energy between the drug and polymer. This high interaction 
energy may play a pivotal role to develop the composite pellets having the drug molecularly 
dispersed in the system. The solid-state analysis revealed the existence of the drug in molecular 
dispersion state during the processing while advanced surface analysis showed a homogenous 
single-phase. Such emerging approach can be utilised to develop controlled release drug delivery 
systems. Moreover, the development of the SH based composite pellets via HME is preferable 
since its preparation is quick, economical with fewer process steps which will make the future 
pilot scale formulation development much easier.  
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TABLE(S) 
 
Table 1: Formulation composition of the SH composite pellets   
Formulation SH 
(%) 
EC N10 
(%) 
EC P7 
(%) 
HPMC 
(%) 
PEG 
(%) 
ATO-888 
(%) 
F1 30 70     
F2 30  70    
F3 30   60 10  
F4 30   60  10 
F5 40 60     
F6 40  60    
 
 
  
 
 
 
 
 
 
 
Figures caption list 
Fig. 1 Molecular modelling to predict drug/polymer intermolecular interaction. 
Fig. 2 Continuous manufacturing process of SH pellets using HME. 
Fig. 3a Optical images of pellets and SEM images of the pellets of SH/polymers. 
Fig. 3b EDS surface analysis of the pellets. 
Fig. 4 AFM images of the composite pellets; (a) phase and (b) topographic images 
of extruded composite pellets. 
Fig. 5a DSC thermal analysis of pure drug and polymers. 
Fig. 5b DSC thermal transition of the physical blends and extruded pellets. 
Fig. 5c HSM images to show the thermal transition of SH in the polymeric matrices. 
Fig. 6 XRPD diffractograms of pure drug, drug/polymer physical mixtures (PM) and 
extruded formulations (EXT). 
Fig. 7 Raman mapping and spectra of (a) physical mixture and (b) the composite 
pellets (F3). 
Fig. 8 Raman mapping and spectra of (a) physical mixture and (b) the composite 
pellets (F4). 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
